Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $22.00 | Overweight | Morgan Stanley |
| 10/10/2024 | $18.00 | Outperform | Raymond James |
| 6/7/2024 | $38.00 | Buy | Goldman |
| 3/11/2024 | $36.00 | Buy | H.C. Wainwright |
| 3/8/2024 | $20.00 → $35.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/6/2024 | $37.00 | Market Perform → Outperform | Leerink Partners |
| 2/21/2024 | $45.00 | Outperform | Raymond James |
| 11/1/2023 | $35.00 | Buy | Stifel |
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosedPhase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomesFunctional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectivelyNew biomarker data confirms consistent robust expression of differentiated RGX-202 microdystrophin in the muscleFavorable safety profile observed at both dose levels; no serious adverse events or AEs of special interest Webcast to be hel
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital, and Michael Kelly, PhD, Ch
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this monthBLA submission for RGX-121 initiated and expected to complete in Q1 2025Positive Phase II data support bilateral administration of subretinal ABBV-RGX-314; data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profileEnd-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy accelerated to Q4 2024 to support global pivotal program initiation in H1 2025Conference call today at 4:30 p.m. ETROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported fi
Morgan Stanley resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $22.00
Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $18.00
Goldman initiated coverage of REGENXBIO with a rating of Buy and set a new price target of $38.00
Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years. "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and
Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. "I could not be more pleased to welcome Drs. Strahlman and Palanki to our Board and look forward to their immediate contributions," stated Dr. Sean Ianchulev, chief executive officer and chief medical officer of Eyenovia. "Each brings decades of medical technology, cl
SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)
SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)
SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases.” Suprachoroidal drug delivery is an ocular route of drug administration. The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion. Meanwhile, SCS injections provide a more targeted and compartmental
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients (patients who can walk) and accelerated approval for non-ambulatory patients (patients who cannot walk). Related: Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months. Continued approval for non-ambulatory Duchenne patients may be contingent upon verification of clinical benefit in a co
10-Q - REGENXBIO Inc. (0001590877) (Filer)
8-K - REGENXBIO Inc. (0001590877) (Filer)
8-K - REGENXBIO Inc. (0001590877) (Filer)
4 - REGENXBIO Inc. (0001590877) (Issuer)
4 - REGENXBIO Inc. (0001590877) (Issuer)
3 - REGENXBIO Inc. (0001590877) (Issuer)
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-s
ROCKVILLE, Md., July 25, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights. To access the live call by phone, dial (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 4849384. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call. Those who plan on participating are advised to join 15 minutes prior
ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage